Published: October 2004
123 pages,
Can be printed; fully searchable PDF format; TOC hyperlinks and Internet hyperlinks
SKU: TPR3153
Price:
$1,695.00 (US Dollars) PDF Single User License
$1,995.00 (US Dollars) PDF Single Office
License (2 to 5 users)
$2,295.00 (US Dollars) PDF Corporate Site
License
Description
This report is about the global market for
prescription drugs and estimates the market outlook to 2008. Readers receive detailed data and analysis about important global pharmaceutical industry
developments. The research report discusses key industry activities including alliances, disease demographics to target major diseases, distribution channels
and market trends.
The research study shows that companies are
facing challenging times ahead as drug patent expirations approach and lists patent expirations to 2008. The development of new drug pipelines and how companies
can get their drugs approved around the globe are also key challenges that the pharmas must face. The report discusses what pharma companies must do to market
and distribute their approved products to patients around the world.
While the global economy has had its ups and
downs, this report projected that the market will grow to about $655.8 billion in 2008 and will grow at a rate of about 7.3% (CAGR).
The pharmaceutical industry faces numerous
challenges that could be helped with newer business approaches. This report looks at the industry from the viewpoint of leading disease categories and reveals
what the key health issues are through disease demographic data from around the globe. This report analyzes the disease categories of the top 276 drug products
and ranks the best selling areas and products. This interesting data is projected to 2008.
Pharma and biotech industry executives, product
managers, marketers, planners, entrepreneurs, VCs, investors, academic researchers and consultants would find this report a useful information source. The
report discusses the numerous pharma industry topics with interesting and useful findings. Thirty-two tables and seventeen figures illustrate the findings.
Detailed information about the business and R&D activities of the top pharma companies is listed in many areas of this report.
Table Of Contents
1.Disease Demographics and the Rx Drug
Market
Pharmaceutical Planning and Disease
Statistics
The Scale of Major Disease Populations
Health Risks and Death Linked to `Modern'
Lifestyle
2.Leading Rx Drugs, Revenues and Drug
Companies
The Leading Twenty Prescription Drugs
Leading Twenty Rx Drugs by Disease
Categories
Leading Twenty Rx Drugs by Top Pharma
Companies
The Best Selling 276 Prescription Drugs
The Best Selling Drugs by Disease
Categories
3.Drug Market Distribution, Price and Cost
Arrangement
Approaches to Regional Price Setting
A Case Study of a Drug Distribution Channel
Distribution Supply Chain and Distributors
Example of How Rx Drugs Reach Patients
(HMO)
4.Pharma Partnering and M&A Trends
Review of Pharmaceutical Partnerships
Comparing Alliances and M&As
Key Findings About Alliances and M&As
Background to the Following Data Tables
5.Patent Expiries and New Drug Pipelines
The Impact of Nearing Patent Expirations
Late Stage Drug Pipeline in 2003
6.Navigating World Drug Regulatory
Organizations Drug
R&D and Regulatory Approval Processes
Drug Approvals in the USA (North America)
Overview of the Drug Approval Process in
the
USA (FDA)
Drug Approvals in the European Union (EU)
Overview of the Drug Approval Process in
the
European Union
`Mutual Recognition' Principle
The Centralized Approval Procedure
Decentralized Approval Procedure
Drug Approvals in Japan
Overview of the Drug Approval Process in
Japan
Applications for Approval of Drugs
Manufactured
Outside of Japan
Japan's Priority Review System
The Orphan Drug Designation
Regional Drug Regulatory Issues to Consider
USA (North America)
The European Union
In Japan
7.The Global Rx Drug Market Size and Outlook
to 2008
Rx Drug Market Size of the Developed World
Selected Top 276) Global Rx Drug Market Size
by
Disease and Revenues
Top Six Market Segments and Subsegments
8.Conclusions and Issues to Consider
Drug Companies Use Disease Demographics
Epidemiology Based Pharmaceutical Planning
Large
Disease Populations Point to Potential
Marketing
Opportunities
Health Risk Factors Lead to Sickness &
Death
Key Points about Global Regulators and
Issues
Need for Government Drug Regulatory
Approval
International Drug R&D and Approval
Processes
Regulatory Trends
Drug Patent Expiration Dates and New Drug
Pipeline Patent Expirations Looming to
Cause Big Losses Current Drug R&D
Pipeline is Weak
Drug Pricing & Distribution Arrangements
Pricing Arrangements
Drug Distribution Supply Chain
Pharma Alliances and M&As
Alliance Trends
Rx Drug Market Size
Best Selling Rx Drugs
Issues to Consider
9.Appendix
Pharmaceutical Business Glossary
Contacts to the Top 55 Pharma Companies
Links to Worldwide Drug Regulatory
Organizations
List of Tables
Table 1. Major Disease Populations by Annual
New Patients
Table 2. Major Disease Populations by Total
Existing
Patients
Table 3. Disease Populations in the Developed
World
Table 4. Major Health Risk Factors Leading to
Death
Table 5. Leading 20 Rx Drugs Global Sales ($M)
Table 6. Leading 15 Disease Categories by
Global Sales
Table 7. Disease Category Definitions Used in
this Section
Table 8. Rx Drugs by Disease Indication and
Global Sales
Table 9. Rx Drug Pricing Tiers and Channels by
Region
Table 9. Rx Drug Pricing Tiers and Channels by
Region
Table 10. Model of US Pricing for Brand Name Rx
Drugs
Table 11. Top Level of US Wholesale Rx Drug
Distribution
Channel
Table 12. Details of the US Retail Pharmacy
Channel
Table 13. Key Rx Drug Distributors by
International Region
Table 14. Map of Pharma Alliances and M&As
Table 15. Pharma Strategic Alliances and M&As
by Major
Disease
Table 16. Alliances and M&As, 2003
Table 17. Alliances and M&As, 2002
Table 18. Alliances and M&As, 2001
Table 19. Alliances and M&As, 2000
Table 20. Summary of Drug Patent Expirations
and Lost
Revenues
Table 21. Drug Patent Expirations to 2008
Table 22. Drug Patent Expirations by Disease
Category and
Indication
Table 23. Drug Pipeline by Clinical Phase in
2003
Table 24. Drug Pipeline Summary by Disease for
2003
Table 25. Late Stage Rx Drug Development
Pipeline (2003)
Table 26. Relationship of Drug Regulation to
Drug
Development
Table 27. Total Audited World Rx Drug Sales by
Regions,
2002
Table 28. Estimated Global Rx Drug Sales by
Regions, 2002-
2008E
Table 29. Top 10 Products in 2002 Global Rx
Drug Sales
Table 30. Top 276 Human Rx Drug Global Market
Size Sorted
by 2003 Revenues ($M) and Disease
Segments
(Summary), 2002-2008E
Table 31. Top 276 Human Rx Drug Global Market
Size Sorted
by CAGR and Disease Segments
(Summary), 2002-2008E
Table 32. Top 276 Human Rx Drug Global Market
Size by
Disease (Detail) ($M) 2002-2008E
List of Illustrations
Figure 1. An Rx Drug Distribution Arrangement
Figure 2. Map of Strategic Alliances and M&As
Figure 3. Selected M&As by Valuation ($M)
Figure 4. Pharma Strategic Alliances and M&As
by Major
Disease
Figure 5. Navigating the Drug R&D and Approval
Process
Figure 6. The US FDA New Drug Approval Process
Flowchart
Figure 7. EU Centralized Drug Approval
Procedure Flowchart
Figure 8. EU Decentralized New Drug Approval
Procedure
Flowchart
Figure 9. Japan MHLW New Drug Approval
Flowchart
Figure 10. Estimated Selected (Top 276) Human
Rx Drug Global
Market Size by Revenues ($M) and
Disease Segments,
2002-2008E
Figure 11. Comparison of Disease Segment Market
Shares for
the Selected (Top 276) Global Human
Rx Drug Market,
2002 and 2008
Figure 12. Market Size by the Estimated
`Cardiovascular'
Segment Revenues, 2002-2008
Figure 13. Market Size by Estimated `CNS'
Subsegment
Revenues, 2002-2008
Figure 14. Market Size by
Estimated `Infections' Subsegment
Revenues, 2002-2008
Figure 15. Market Size by Estimated
`Respiratory & Allergy'
Subsegment Revenues, 2002-2008
Figure 16. Market Size by the Estimated
`Gastrointestinal'
Subsegment Revenues, 2002-2008
Figure 17. Market Size by the
Estimated `Cancer' Subsegment
Revenues, 2002-2008
For more information or to order the above publications,
call 1-510-796-9129 or fax 1-510-796-9129.
Copyright © 1996-2012 TAKEDA PACIFIC. All Rights Reserved.